When Clinicians Switch Sooner: New TRD Dosing Guidance

Psychiatrists Are Calling for Faster, Smarter TRD Treatment Decisions

A clinical review published this week in Psychiatric Times is pushing psychiatrists to act faster and more precisely when treating patients with treatment-resistant depression (TRD) using NMDA receptor antagonists — the drug class that includes IV ketamine and FDA-approved intranasal esketamine (Spravato). The review synthesizes current data on side effect profiles and discontinuation rates, arriving at a pointed message for providers: optimize doses sooner, switch treatments earlier when response is inadequate, and systematically track outcomes using validated tools like the PHQ-9.

For patients exploring online ketamine therapy in 2026, this signals something important: the clinical standards around ketamine care are maturing rapidly, and the bar for what responsible treatment looks like — including in telehealth settings — is rising.

What the Data Actually Shows

NMDA antagonists share a recognizable short-term side effect profile: dissociation, dizziness, nausea, elevated blood pressure, and mild sedation during or shortly after treatment. These effects are typically transient, resolving within hours, but their intensity varies considerably by dose, route of administration, and individual patient sensitivity. The Psychiatric Times review underscores that discontinuation rates — patients who stop treatment before completing a full course — remain a meaningful clinical concern, and that many of these dropouts are preventable.

A central recommendation in the review: track PHQ-9 scores at every session rather than waiting until a full induction course ends to assess progress. The evidence shows that early response — roughly a 50% or greater reduction in PHQ-9 score by sessions three or four — is one of the strongest predictors of sustained remission. Providers who wait passively for end-of-course results are missing the window to intervene when it matters most.

Why Telehealth Ketamine Patients Should Pay Attention

The telehealth ketamine market has expanded considerably since 2023, and with that growth has come significant variation in care quality. Some online providers conduct thorough psychiatric intake evaluations, require regular follow-up check-ins, and adjust protocols based on patient-reported outcomes. Others operate more transactionally — prescribing and shipping with little monitoring in between.

The clinical guidance in this review implicitly raises the bar for what responsible online ketamine care should include. If in-person psychiatrists are being urged to track PHQ-9 scores session-by-session and make proactive adjustments based on side effect burden and treatment response, that same expectation should apply — arguably even more rigorously — to telehealth providers who cannot observe patients directly during sessions.

This gives patients a concrete screening criterion when evaluating providers: does the service you're considering actually track your depression scores over time? Do they have a protocol for adjusting your dose if acute side effects are significant or improvement isn't emerging? According to the current clinical consensus, these aren't premium features — they're baseline standards of care.

Discontinuation Risk Is Real — and Largely Preventable

One of the more actionable takeaways from this review is that discontinuation risk isn't random. Patients who receive clear pre-treatment education about what to expect, who feel supported by their clinical team through side effects, and whose providers detect early non-response quickly are significantly more likely to complete their treatment course. Patients who feel blindsided by dissociation, or who quietly wait out several sessions with no improvement and no clinical feedback, are at highest risk of dropping out prematurely.

This means provider communication quality is as pharmacologically important as dosing precision. A good telehealth ketamine provider should be explaining the acute effects before treatment begins, normalizing the dissociative experience so it isn't alarming, and actively checking in on both efficacy and tolerability between sessions. For patients who previously tried ketamine and discontinued, it's worth asking honestly: was that a treatment failure, or a management gap that a different provider might have handled differently?

Practical Steps for Patients in 2026

Several concrete implications emerge from this research for anyone currently receiving or considering online ketamine treatment:

• Ask how your progress is tracked. A provider without a systematic outcome measurement tool has limited ability to make evidence-based decisions about your care. PHQ-9 or MADRS scores at every session should be standard.
• Expect dose flexibility. Ketamine dosing is not one-size-fits-all. If a provider has never discussed adjusting your protocol based on how you're responding, that's a yellow flag worth raising directly.
• Side effects don't mean treatment failure. Dissociation, nausea, and temporary blood pressure changes are expected and generally manageable. A quality provider will contextualize these effects and help determine whether they're transient or worth adjusting for.
• Early non-response warrants a conversation, not continued waiting. If you're several sessions in and seeing no signal of improvement, clinical guidance supports proactive intervention — not continued passive treatment. Ask your provider what happens next if you don't respond.

The trajectory of clinical research on NMDA antagonists is broadly encouraging for TRD patients. The field is moving toward more precise, patient-centered care with measurable accountability at every step. For patients choosing an online ketamine provider, the standard you should expect from your care team is the same one the clinical literature now expects from in-person psychiatrists: track outcomes, manage side effects proactively, and don't wait too long to change course when the data says to.